Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.
Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.